<DOC>
	<DOCNO>NCT00005958</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combination chemotherapy gemcitabine docetaxel plus filgrastim treating patient locally recurrent advanced urothelium cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Filgrastim Treating Patients With Locally Recurrent Advanced Urothelium Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy gemcitabine , docetaxel , filgrastim ( G-CSF ) patient locally recurrent advance transitional cell carcinoma urothelial tract . II . Determine toxicity regimen patient . III . Determine disease-free overall survival patient population treat regimen . OUTLINE : This multicenter study . Patients stratify accord prior chemotherapy ( yes v ) . Patients receive gemcitabine IV 30 minute day 1 8 docetaxel IV 1 hour day 8 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 9 continue blood count recover . Treatment continue every 3 week 4 course absence disease progression unacceptable toxicity . Patients respond treatment may undergo surgery 6-8 week later receive 2 course chemotherapy . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 23-40 patient receive prior chemotherapy 23 patient receive prior chemotherapy accrue study within 2 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally recurrent advance transitional cell carcinoma ( TCC ) urothelial tract ( bladder , renal pelvis , ureter ) TCC squamous cell glandular element amenable curative treatment No pure squamous cell carcinoma adenocarcinoma Regional distant metastasis cystoprostatectomy No brain metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 80100 % Life expectancy : At least 3 month Hematopoietic : No hemorrhagic disorder Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10.0 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known sensitivity product administer E. coli derive product No prior malignancy except inactive nonmelanoma skin cancer , adequately treated stage I II cancer complete remission , early stage prostate cancer ( currently treat ) No illness psychiatric condition would preclude study follow Not previously enter study No active uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy No concurrent WBC transfusion Chemotherapy : No prior gemcitabine docetaxel Other prior chemotherapy allow Prior intravesical therapy allow No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy renal pelvis ureter allow Surgery : See Disease Characteristics Cystoprostatectomy nephroureterectomy localize TCC allow Other : No prior investigational drug No concurrent investigational therapy No concurrent acetaminophen fever prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>